Malaysian shares experienced a decline on Wednesday, putting an end to a five-day winning streak. The benchmark FTSE Bursa Malaysia KLCI (FBMKLCI) dropped by 0.8% to 1,486.86.
Top Losers
- Hartalega Holdings (5168), a health care/life sciences firm, recorded the largest decline with a fall of 3.3%.
- Shares of financial services company Public Bank (1295) also dropped by 1.8%.
- Real estate/construction company Gamuda (5398) saw a decline of 1.8%.
Top Gainers
- Inari Amertron (0166), a technology company, was the biggest leader during the session, witnessing a gain of 1.3%.
- Agriculture firm QL Resources (7084) increased by 0.9%.
- Nestle (Malaysia) (4707), operating in the consumer goods sector, rounded out the top three leaders on Wednesday, with shares gaining 0.8%.
Other Southeast Asian Markets
In other parts of Southeast Asia, the FTSE Straits Times Index (STI) in Singapore declined by 0.6%. Meanwhile, the Thailand SET Index (SET) fell by 0.2%. The Philippines' PSEi Index (PSEI) witnessed a decline of 1.1%, while Indonesia's JSX Composite Index (JAKIDX) added 0.4%.
Asian Markets Overview
Across the Asia-Pacific region, Hong Kong stocks experienced a drop, with the Hang Seng Index down by 0.6%. On the positive side, the NIKKEI 225 Index of Japanese companies rose by 2.0%, while China's Shanghai Composite Index declined by 0.5%.
South Korea's KOSPI Composite Index declined by 0.8%, and the S&P/ASX 200 Benchmark Index of Australian stocks fell by 0.7%.
Currency Update
As for the currency market, the U.S. dollar fell by 0.1% to 4.64 Malaysian ringgit, while the euro climbed by 0.1% to 5.08 ringgit.
Our Latest News
Domino’s Pizza Profit Boost
Domino’s Pizza Inc. shares rise after profit beat. Revenue flat. CEO positive on business momentum. Dividend increase.
Strong Momentum for On the Beach Group in Fiscal 2024
On the Beach Group experiences rise in profit and positive momentum in fiscal 2023, predicts successful Summer '24. Strong progress into fiscal 2024 fueled by f...
AbbVie Raises Profit Outlook as Immunology Drugs Drive Sales
Biopharmaceutical company AbbVie raises profit outlook for 2023 as newer immunology drugs drive sales, compensating for decline in Humira revenue.